ESCMID eLibrary
Search results
Icon explanation
Icon explanation
close
Abstract
ePoster
Handout
Image
Journal Article
Presentation
Video
Webcast
Found 19 results
-
Future perspectives – clinical breakpoints and dosing in 20 years?
12 April 2019
Session: Future perspectives – clinical breakpoints and dosing in 20 years?
Relevance:100%
-
P1539
In vitro activity of cefepime alone and in combination with the broad-spectrum beta-lactamase inhibitor VNRX-5133 against ESBL and carbapenamases harbouring Enterobacteriaceae and Pseudomonas spp.
23 April 2018
Session: VNRX- 5133 plus cefepime: in vitro and in vivo data
Relevance:100% -
W0014
Carbapenem and aminoglycoside breakpoints revisited
21 April 2018
Session: Antimicrobial susceptibility testing with EUCAST breakpoints and methods
Relevance:100%
-
EP0943
Population pharmacokinetics, Monte Carlo simulations and dosing recommendations of cefepime using 2h infusion, including renal impairment
25 April 2017
Session: Recent advances in PK/PD: efficacy and toxicity
Relevance:100%
-
OS1020
Population pharmacokinetics of Murepavadin (POL7080) and Monte Carlo simulations to develop clinical dosing regimens, including the renally impaired
25 April 2017
Session: PK/PD: what you need to learn for new and old-revived antibiotics
Relevance:100%
-
P1299
Population pharmacokinetics of zidebactam (WCK 5107), a novel beta-lactam enhancer antibiotic
24 April 2017
Session: Zidebactam and other new Gram-negative antibiotic potentiators
Relevance:100% -
P1179
Population pharmacokinetics, Monte Carlo simulations and dose adjustment of tazobactam including in the renally impaired
24 April 2017
Session: PK/PD studies in humans
Relevance:100% -
Current tools and approaches for setting breakpoints
21 September 2016
Relevance:100% -
Setting breakpoints for EUCAST
20 September 2016
Relevance:100% -
New approaches to circumvent Staphylococcus multiresistance
01 July 2016
Relevance:100%
Search narrowed by
-
Topics
-
Type of material
-
Time period
